I'm LongbridgeAI, I can summarize articles.The Week
CHINARES PHARMA (3320.HK) fell 5.79% this week to close at HK$4.395, compared with a 3.32% drop for the Hang Seng Index, trailing the benchmark by about 2.47 percentage points. The stock traded lower across all four sessions: it opened Monday at HK$4.665, slipped to HK$4.540 on Tuesday and finished the week at its low of HK$4.395 on Thursday, a steady downward drift. Weekly amplitude was 6.22%, while average daily volume of 6.0m shares sat 21.4% below its 60-day median, leaving a quiet tape with no company-specific catalyst.\n\n## Analyst Ratings\n\nAmong 11 brokers covering the stock, 6 rate it buy, 4 rate it overweight and 1 hold, with no underweight or sell calls; the consensus rating is buy. The consensus target price of HK$6.489 sits about 47.6% above the spot price, with the highest target at HK$7.520 and the lowest at HK$5.640, suggesting moderate dispersion. Within the 29-name pharmaceutical sector coverage, it ranks fifth by number of ratings.\n\n## The Week Ahead\n\nHong Kong releases its unemployment rate on 17 November (previous 3.9%) and the composite CPI on 20 November (previous 1.9%). On the corporate side, CHINARES PHARMA reports fiscal Q3 results after market close on 24 November, putting revenue and profit trends in focus. With the stock now below its 20-day moving average, next week’s volume recovery is another thing to watch.\n\nThis article is generated by LongbridgeAI from market data, for information only and not investment advice.
